Clene (NASDAQ:CLNN) Receives Buy Rating from D. Boral Capital

Key Points

• D. Boral Capital reiterated a "buy" on CLNN with a $23 price target — implying roughly 217% upside — and the stock has a consensus "Moderate Buy" from analysts with an average target of $34 (Canaccord's target is $48).
• Clene reported Q1 EPS of ($0.88), missing the ($0.74) estimate while generating just $0.08M in revenue, and analysts forecast a full-year EPS around -1.99, underscoring its unprofitable clinical-stage profile and $85M market cap.
• A major insider sold 5,736 shares at $6.08 and insiders sold 159,084 shares (~$931,704) over the last quarter, though insiders still own about 28.3% of the company and institutions hold roughly 23.3%.

Clene (NASDAQ:CLNN - Get Free Report)'s stock had its "buy" rating restated by stock analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $23.00 price target on the stock. D. Boral Capital's price objective would indicate a potential upside of 217.37% from the stock's previous close.

Several other equities analysts also recently issued reports on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $48.00 price target on shares of Clene in a report on Friday, March 13th. Weiss Ratings lowered Clene from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, April 22nd. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $34.00.

Clene Price Performance

Shares of CLNN stock opened at $7.25 on Monday. The stock's fifty day simple moving average is $5.68 and its 200 day simple moving average is $6.47. Clene has a one year low of $2.28 and a one year high of $13.50. The firm has a market cap of $85.37 million, a price-to-earnings ratio of -2.86 and a beta of 0.89.

Clene (NASDAQ:CLNN - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The business had revenue of $0.08 million during the quarter, compared to analysts' expectations of $0.03 million. On average, research analysts anticipate that Clene will post -1.99 earnings per share for the current year.

Insider Buying and Selling at Clene

In related news, major shareholder Chidozie Ugwumba sold 5,736 shares of the firm's stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $6.08, for a total transaction of $34,874.88. Following the completion of the transaction, the insider directly owned 277,569 shares of the company's stock, valued at $1,687,619.52. This trade represents a 2.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 159,084 shares of company stock valued at $931,704 over the last quarter. Insiders own 28.30% of the company's stock.

Institutional Investors Weigh In On Clene

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of Clene during the 2nd quarter worth approximately $47,000. Scoggin Management LP raised its holdings in shares of Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company's stock valued at $558,000 after purchasing an additional 42,750 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Clene during the third quarter valued at about $29,000. Lunt Capital Management Inc. boosted its holdings in Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company's stock worth $315,000 after purchasing an additional 1,250 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Clene by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company's stock worth $482,000 after purchasing an additional 6,090 shares in the last quarter. 23.28% of the stock is currently owned by institutional investors.

About Clene

Clene NASDAQ: CLNN, also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.